Benzinga
04 Mar 2026, 17:59 UTC · 29w ago
Verdict
Headline takes no side. We score SLS +1.00 across four claims — strongly bullish.
+1.00strongly bullish
More positive than 99% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
The Phase 2 study of SLS009 in combination with AZA/VEN for R/R AML patients showed a 46% overall response rate and a median overall survival of 8.9 months in the least pretreated cohort.
So whatPositive clinical data for a cancer drug is a primary driver of valuation and risk appetite for biotech stocks.
More positive than 93% of claims this week
The Phase 3 REGAL trial had recorded 72 of the 80 required events as of December 26, 2025, bringing the study closer to final analysis.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 79% of claims this week
SELLAS Life Sciences has a short interest of 27.21%, making it a potential candidate for a short squeeze.
More positive than 66% of claims this week
The stock's RSI is currently at 72.66, suggesting it may be overbought in the short term.
More negative than 68% of claims this week
Which stocks this story touches
More positive than 99% of ticker scores this week
The company has seen significant stock price growth, positive clinical data from Phase 2 and Phase 3 trials, and strong bullish technical indicators.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Seeking Alpha
8h ago
+116.8%
Price agrees with the score
$11.51 vs $5.31 close before publication (Mar 3) · not market-adjusted
SLS chart →
